These differences in case definition and antibody profiles offer a coherent explanation for why central nervous system involvement predominated in our PD-1/PD-L1 inhibitor–related PNS cohort, even though peripheral neuropathy is more prominent in the broader n-irAE literature. The gene discussed is CD274; the disease is peripheral neuropathy.